openPR Logo
Press release

Leprosy Treatment Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2016–2024

04-12-2017 04:19 PM CET | Health & Medicine

Press release from: CMI

Leprosy Treatment Market – Global Industry Insights, Trends,

Leprosy or Hansen's disease (HD) is a chronic infection caused by Mycobacterium lepromatosis or Mycobacterium leprae bacteria. Leprosy is principally a granulomatous disease. Symptoms of leprosy include reddish skin lesions, loss of sensation, and weakness of hands and muscles. Nerve damage is the primary cause for numbness of muscles. Leprosy is a communicable disease that can be propagated through contact with cough or phlegm of the affected person. Other risk factors of leprosy include malnutrition and weak immune system. Leprosy is especially prevalent in low-income countries.

Leprosy Treatment Market Outlook

According to the statistics received by the World Health Organization (WHO), from various regions (138 countries), the number of registered cases of leprosy was 176,176 in 2015, that is 0.18 cases per 10 000 people. The number of new cases shows the degree of sustained transmission of the disease. Global statistics illustrate that 203,600 (96%) of fresh leprosy cases were from 22 key countries. Prevalence of high occurrences is a reminder that some areas around the world show high incidences of the disease and experience very high rate of transmission. According to WHO, around 16 million cases of leprosy have been treated in the last two decades. Governing bodies and governments alike are trying to eradicate the presence of the disease on a global scale. Owing to these factors, the leprosy treatment market is expected to grow at substantial rate over the forecast period (2016–2024).

Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-sample/128

Leprosy Treatment Market Taxonomy

On the basis of type of leprosy, the global leprosy treatment market is classified into:

Early and indeterminate leprosy treatment
Borderline tuberculoid leprosy treatment
Tuberculoid leprosy treatment
Borderline leprosy treatment
Histoid leprosy treatment
Lepromatous leprosy treatment
Borderline lepromatous leprosy treatment
Diffuse leprosy of Lucio and Latapí
On the basis of treatment, the global leprosy treatment market is classified into:

Multidrug Therapy
Others
On the basis of type of end user, the global leprosy treatment market is classified into:

Government
Hospitals
Medical Practitioners
Others

As per National Leprosy Eradication Programme (NLEP), leprosy has been broadly categorized into two segments namely, paucibacillary leprosy (one to five skin lesions, maximum one nerve with skin liaisons) and multibacillary leprosy (over six skin liaisons, more than one nerve with skin liaisons). Early detection of the disease is an important factor for effective treatment, though various drugs are available for late stage leprosy patients. The most common treatment is multidrug therapy. The drugs recommended by WHO multidrug therapy are rifampicin, dapsone, and clofazimine. Among these, rifampicin is most preferred for treatment of leprosy. Treatment with everyday dapsone and monthly treatment with rifampcin for six months is followed for paucibacillary (PB or tuberculoid) cases. For multibacillary (MB or lepromatous) cases, the treatment is a prolongrd one. It includes daily dapsone and clofazimine. Additionally, monthly rifampicin is recommended for 12 months. Side effects, resistance, and relapse rate are low in multidrug therapy. Some of the other drugs available for leprosy treatment are rifadine and rimactane. The leprosy treatment market is projected to witness a steep inlince in the number of novel drugs and availability of the same, due to increasing initiatives across the globe to eradicate this menace.

Leprosy Treatment Market Future Outlook: Asia Pacific to be Key Growth Market

Leprosy has been endemic to mankind since many decades. This needed interference of various governments around the world as well as the World Health Organization. Governments play an important role in the leprosy treatment market. Ever since the introduction of multidrug therapy by WHO in 1982, governments around the world have adopted this treatment procedure on a large scale. Some of them subsidized the treatment to eradicate the presence of the disease from their countries. Therefore government regulation as well as adoption remains the most important driver of the leprosy treatment market.

Request For TOC: https://www.coherentmarketinsights.com/ongoing-insight/toc/128

Asia Pacific, especially India remains one of the most affected countries. As per the World Health Organization reports, about 59% of the new cases reported were from India. According to stats released by the Leprosy Mission Trust, around 127,000 new occurrences of leprosy were reported from India alone during 2013–2014. Out of these, about 46% were women and children. In India, the prevalence rate according to The Leprosy Mission Trust in the year 2014 was about 0.68 per 10,000 population. The National Leprosy Eradication Programme (NLEP) is one such initiative by the Indian government that aims to eradicate the disease from the country by 2018. Therefore, leprosy treatment market in this region is projected to grow at a considerable rate in the near future.

Key Players in Leprosy Treatment Market

Companies operating in the leprosy treatment market include Glaxo Smithcline Pharmaceuticals Ltd., Systopic Laboratories Pvt. Ltd., Acme Pharmaceuticals, Cadila Pharmaceuticals, Macleods Pharmaceuticals, IDPL, Astra Zeneca Pharma India Ltd., Lark Laboratories (UIndia) Ltd., Genetic Pharma, and Novartis International AG.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

CONTACT US:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel : +1-206-701-6702
Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Leprosy Treatment Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2016–2024 here

News-ID: 499774 • Views: 250

More Releases from CMI

Natural And Organic Flavor Market To Reach Around US$ 10.6 Billion By 2027
CMI published a business research report on “Natural and Organic Flavors: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2018–2026”. Natural and Organic Flavors with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. The information is gathered based on modern floats and requests identified with the administrations and items. The Natural and Organic Flavors report stresses the most recent
Chocolate Market By product type, By distribution channeland By region 2027 | Ke …
CMI published a business reserch report on “Chocolate: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2018–2026”. Chocolate with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. The information is gathered based on modern floats and requests identified with the administrations and items. The Chocolate report stresses the most recent advancements, development, new chances, and lethargic traps. It gives
What is the current Trend onVideo telemedicine? Huawei technologies Co. Ltd., Po …
Video telemedicine for treating patients is important aspects of telemedicine facility, which facilitates reliable quality and clinical efficiency to in-home care, acute care and ambulatory care. Telehealth continue to gain importance in healthcare industry. Patients are realizing the value of virtual care options and substituting it for in-patient care option. Telemedicine extends the healthcare solutions to the rural patients and to the patients living in the remote location areas, which
11-11-2019 | Health & Medicine
CMI
Robust research and development activities for development of novel oral biologi …
Key players are involved in extensive research and development of novel oral biologics for various conditions In February 2019, researchers at Massachusetts Institute of Technology (MIT) developed a drug capsule with the potential to deliver an oral insulin named SOMA capsule, thereby replacing (or eliminating) the need to administer insulin via injections multiple times a day for patients with type 1 diabetes. The researchers stated that the drugs is currently under

All 5 Releases


More Releases for Leprosy

Leprosy Treatment Market to Reap Excessive Revenues by 2028(Based on drug class …
Leprosy is a chronic infectious disease caused by Mycobacterium leprae. Leprosy is also known as Hansen’s disease. It affects the skin, mucosal surfaces of the upper respiratory tract, the peripheral nerves and the eyes. Leprosy can occur in people of all ages, from infants to the elderly. The exact transmission of the disease is not known, but it is strongly believed that leprosy is transferred from a leprosy patient to
Leprosy Treatment Market Opportunity Analysis, 2018-2026
Leprosy or Hansen's disease (HD) is a chronic infection caused by Mycobacterium lepromatosis or Mycobacterium leprae bacteria. Leprosy is principally a granulomatous disease. Symptoms of leprosy include reddish skin lesions, loss of sensation, and weakness of hands and muscles. Nerve damage is the primary cause for numbness of muscles. Leprosy is a communicable disease that can be propagated through contact with cough or phlegm of the affected person. Other risk
Global Leprosy Treatment Market Industry Trend and Forecast 2025
This report focuses on the global Leprosy Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Leprosy Treatment development in United States, Europe and China. Leprosy, also known as Hansen's disease (HD), is a long-term infection by the bacterium Mycobacterium leprae or Mycobacterium lepromatosis. Initially, infections are without symptoms and typically remain this way for 5 to 20 years. Symptoms that develop
Leprosy Treatment Market Positive long-term growth outlook 2018-2026
Leprosy Treatment Market report 2018-2026 focuses on the major drivers and restraints for the key players. These research report also provides granular analysis of the market share, segmentation, revenue forecasts and geographic regions of the market. The Leprosy Treatment market research report is a professional and in-depth study on the current state of Leprosy Treatment Industry. The Leprosy Treatment Market research report covers the present scenario and the growth prospects of
Leprosy Vaccines Market Promising Growth Opportunities over 2018 to 2028
Leprosy is chronic infectious disease caused by Mycobacterium leprae. Leprosy is also referred to as Hansen’s disease. Leprosy affects the skin, mucosal surfaces of the upper respiratory tract, the peripheral nerves and the eyes. Leprosy can occur to the people of all ages from infant to geriatric. The exact reason for transmission of leprosy is not known but it is strongly believed that leprosy is transferred from a leprosy patient
Leprosy Treatment Market Research Report by Regional Analysis : forecast 2024
Leprosy or Hansen's disease (HD) is a chronic infection caused by Mycobacterium lepromatosis or Mycobacterium leprae bacteria. Leprosy is principally a granulomatous disease. Symptoms of leprosy include reddish skin lesions, loss of sensation, and weakness of hands and muscles. Nerve damage is the primary cause for numbness of muscles. Leprosy is a communicable disease that can be propagated through contact with cough or phlegm of the affected person. Other risk